Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: A two-phase randomized controlled trial

Drug and Alcohol Dependence

Volumn 133, Issue 1, 2013, Pages 188-197

  Lofwall, Michelle R ^a,b   Babalonis, Shanna ^a,b   Nuzzo, Paul A ^a   Siegel, Anthony ^a   Campbell, Charles ^b   Walsh, Sharon L ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Department of Behavioral Science ^*  (United States)

Author keywords

Efficacy; Opioid withdrawal; Prescription opioid dependence; Randomized clinical trial; Tramadol; Treatment

Indexed keywords

HYDROCORTISONE; PLACEBO; TRAMADOL;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENDED DRUG RELEASE; FEMALE; FLANK PAIN; GROUP B STREPTOCOCCAL INFECTION; HOT FLUSH; HUMAN; INSOMNIA; IRRITABILITY; LACRIMATION; MALE; MUSCLE TONE; OPIATE ADDICTION; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; SNEEZING; SORE THROAT; TACHYCARDIA; THORAX PAIN; URINE RETENTION; WITHDRAWAL SYNDROME;

EFFICACY; OPIOID WITHDRAWAL; PRESCRIPTION OPIOID DEPENDENCE; RANDOMIZED CLINICAL TRIAL; TRAMADOL; TREATMENT;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; SUBSTANCE WITHDRAWAL SYNDROME; TRAMADOL;

EID: 84884415859     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.05.010     Document Type: Article

References (66)

1. Substance Abuse and Mental Health Services Administration (SAMHSA), 2011. Results from the 2010 National Survey on Drug Use and Health (NSDUH): Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD.
2. Babalonis S., Lofwall M.R., Nuzzo P.A., Siegel A.J., Walsh S.L. Abuse liability and reinforcing efficacy of oral tramadol in humans. Drug Alcohol Depend. 2013, 129:116-124.
3. Barann M., Urban B., Stamer U., Dorner Z., Bonisch H., Bruss M. Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur. J. Pharmacol. 2006, 531:54-58.
4. Barsotti C.E., Mycyk M.B., Reyes J. Withdrawal syndrome from tramadol hydrochloride. Am. J. Emerg. Med. 2003, 21:87-88.
5. Beck A.T., Steer R.A. Internal consistencies of the original and revised Beck Depression Inventory. J. Clin. Psychol. 1984, 40:1365-1367.
6. Benziger D.P., Kaiko R.F., Miotto J.B., Fitzmartin R.D., Reder R.F., Chasin M. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. J. Pharm. Sci. 1996, 85:407-410.
7. Benziger D.P., Miotto J., Grandy R.P., Thomas G.B., Swanton R.E., Fitzmartin R.D. A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone. J. Pain Symptom Manage. 1997, 13:75-82.
8. Brands B., Blake J., Sproule B., Gourlay D., Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend. 2004, 73:199-207.
9. Cicero T.J., Adams E.H., Geller A., Inciardi J.A., Munoz A., Schnoll S.H., Senay E.C., Woody G.E. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend. 1999, 57:7-22.
10. Cicero T.J., Inciardi J.A., Adams E.H., Geller A., Senay E.C., Woody G.E., Munoz A. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol. Drug Saf. 2005, 14:851-859.
11. Compton W.M., Volkow N.D. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006, 81:103-107.
12. Cox D.R. Regression models and life-tables. J. R. Stat. Soc. Series B Stat. Methodol. 1972, 34:187-220.
13. Derogatis L.R., Rickels K., Rock A.F. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br. J. Psychiatry 1976, 128:280-289.
14. Desmeules J.A., Piguet V., Collart L., Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br. J. Clin. Pharmacol. 1996, 41:7-12.
15. Eissenberg T., Greenwald M.K., Johnson R.E., Liebson I.A., Bigelow G.E., Stitzer M.L. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J. Pharmacol. Exp. Ther. 1996, 276:449-459.
16. Enggaard T.P., Poulsen L., Arendt-Nielsen L., Brosen K., Ossig J., Sindrup S.H. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth. Analg. 2006, 102:146-150.
17. Epstein D.H., Preston K.L., Jasinski D.R. Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol. Psychol. 2006, 73:90-99.
18. Fliegert F., Kurth B., Gohler K. The effects of tramadol on static and dynamic pupillometry in healthy subjects - the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur. J. Clin. Pharmacol. 2005, 61:257-266.
19. Freye E., Levy J. Acute abstinence syndrome following abrupt cessation of long-term use of tramadol (Ultram): a case study. Eur. J. Pain 2000, 4:307-311.
20. Gillen C., Haurand M., Kobelt D.J., Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 362:116-121.
21. Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addict. Behav. 1990, 15:487-490.
22. Gutstein H.B., Akil H. Chapter 21 opioid analgesics. Goodman and Gillman's The Pharmacologic Basis of Therapeutics 2006, McGraw Hill, New York. eleventh ed. L.L. Brunton, J.S. Lazo, K. Parker (Eds.).
23. Hair P.I., Curran M.P., Keam S.J. Tramadol extended-release tablets. Drugs 2006, 66:2017-2027. (discussion 2028-2030).
24. Handelsman L., Cochrane K.J., Aronson M.J., Ness R., Rubinstein K.J., Kanof P.D. Two new rating scales for opiate withdrawal. Am. J. Drug Alcohol Abuse 1987, 13:293-308.
25. IMS Health, 2012. National Prescription AuditTM, Top 25 Pharmaceutical Products by Dispensed Prescriptions in the US Market. http://www.imshealth.com/.
26. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 1991, 86:1119-1127.
27. Hennies H.H., Friderichs E., Schneider J. Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung 1988, 38:877-880.
28. Hughes J.R. Tobacco withdrawal in self-quitters. J. Consult. Clin. Psychol. 1992, 60:689-697.
29. Inciardi J.A., Cicero T.J., Munoz A., Adams E.H., Geller A., Senay E.C., Woody G.E. The diversion of ultram, ultracet, and generic tramadol HCL. J. Addict. Dis. 2006, 25:53-58.
30. Jasinski D.R., Preston K.L., Sullivan J.T., Testa M. Abuse potential of oral tramadol. NIDA Res. Monogr. 1993, 132:103.
31. Lai J., Ma S.W., Porreca F., Raffa R.B. Tramadol M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur. J. Pharmacol. 1996, 316:369-372.
32. Lanier R.K., Lofwall M.R., Mintzer M.Z., Bigelow G.E., Strain E.C. Physical dependence potential of daily tramadol dosing in humans. Psychopharmacology (Berl) 2010, 211:457-466.
33. Leo R.J., Narendran R., DeGuiseppe B. Methadone detoxification of tramadol dependence. J. Subst. Abuse Treat. 2000, 19:297-299.
34. Lofwall M.R., Walsh S.L., Bigelow G.E., Strain E.C. Modest opioid withdrawal suppression efficacy of oral tramadol in humans. Psychopharmacology (Berl) 2007, 194:381-393.
35. Lofwall M.R., Moody D.E., Fang W.B., Nuzzo P.A., Walsh S.L. Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers. J. Clin. Pharmacol. 2012, 52:600-606.
36. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. J. Am. Med. Assoc. 2000, 284:1689-1695.
37. McLellan A.T., Luborsky L., Cacciola J., Griffith J., Evans F., Barr H.L., O'Brien C.P. New data from the Addiction Severity Index. Reliability and validity in three centers. J. Nerv. Ment. Dis. 1985, 173:412-423.
38. McLeod D., Griffiths R.R., Yingling J. An automated version of the digit symbol substitution test (DSST). Behav. Res. Methods Instrum. 1982, 14:463-466.
39. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987, 30:191-197.
40. Meyboom R.H., Brodie-Meijer C.C., Diemont W.L., van Puijenbroek E.P. Bladder dysfunction during the use of tramadol. Pharmacoepidemiol. Drug Saf. 1999, 8(Suppl. 1):S63-S64.
41. Moore B.A., Fiellin D.A., Barry D.T., Sullivan L.E., Chawarski M.C., O'Connor P.G., Schottenfeld R.S. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J. Gen. Intern. Med. 2007, 22:527-530.
42. Nielsen S., Hillhouse M., Thomas C., Hasson A., Ling W. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J. Addict. Med. 2013, 7:33-38.
43. Ortho-McNeil, I., 2006. Ultram ER (Tramadol HCl Extended Release Tablets) Package Insert LB0047-01.
44. Poyhia R., Seppala T., Olkkola K.T., Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br. J. Clin. Pharmacol. 1992, 33:617-621.
45. Preston K.L., Jasinski D.R., Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend. 1991, 27:7-17.
46. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., Vaught J.L. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J. Pharmacol. Exp. Ther. 1992, 260:275-285.
47. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., Vaught J.L., Jacoby H.I., Selve N. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J. Pharmacol. Exp. Ther. 1993, 267:331-340.
48. Rodriguez Villamanan J.C., Albaladejo Blanco C., Sanchez Sanchez A., Carvajal A., Martin Arias L., Garcia del Pozo J. Withdrawal syndrome after long-term treatment with tramadol. Br. J. Gen. Pract. 2000, 50:406.
49. Rosenblum A., Joseph H., Fong C., Kipnis S., Cleland C., Portenoy R.K. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. J. Am. Med. Assoc. 2003, 289:2370-2378.
50. Rosenblum A., Parrino M., Schnoll S.H., Fong C., Maxwell C., Cleland C.M., Magura S., Haddox J.D. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007, 90:64-71.
51. Sigmon S.C. Characterizing the emerging population of prescription opioid abusers. Am. J. Addict. 2006, 15:208-212.
52. Sigmon S.C., Wong C.J., Chausmer A.L., Liebson I.A., Bigelow G.E. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction 2004, 99:1439-1449.
53. Simpson D.D., Joe G.W., Rowan-Szal G.A. Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend. 1997, 47:227-235.
54. Sobey P.W., Parran T.V., Grey S.F., Adelman C.L., Yu J. The use of tramadol for acute heroin withdrawal: a comparison to clonidine. J. Addict. Dis. 2003, 22:13-25.
55. Spitzer R.L., Williams J.B., Gibbon M., First M.B. The Structured Clinical Interview for DSM-III-R (SCID) I: history, rationale, and description. Arch. Gen. Psychiatry 1992, 49:624-629.
56. Stoops W.W., Hatton K.W., Lofwall M.R., Nuzzo P.A., Walsh S.L. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl) 2010, 212:193-203.
57. Stoops W.W., Lofwall M.R., Nuzzo P.A., Craig L.B., Siegel A.J., Walsh S.L. Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment. Psychopharmacology (Berl) 2012, 223:427-438.
58. Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J. Pharmacol. Exp. Ther. 1995, 272:628-638.
59. Tamaskar R., Parran T.V., Heggi A., Brateanu A., Rabb M., Yu J. Tramadol versus buprenorphine for the treatment of opiate withdrawal: a retrospective cohort control study. J. Addict. Dis. 2003, 22:5-12.
60. Tiffany S.T., Drobes D.J. The development and initial validation of a questionnaire on smoking urges. Br. J. Addict. 1991, 86:1467-1476.
61. Tjaderborn M., Jonsson A.K., Ahlner J., Hagg S. Tramadol dependence: a survey of spontaneously reported cases in Sweden. Pharmacoepidemiol. Drug Saf. 2009, 18:1192-1198.
62. Toll B.A., Schepis T.S., O'Malley S.S., McKee S.A., Krishnan-Sarin S. Subjective reactivity to the first cigarette of the day as a predictor of smoking relapse: a preliminary study. Drug Alcohol Depend. 2007, 89:302-305.
63. Weiss R.D., Potter J.S., Fiellin D.A., Byrne M., Connery H.S., Dickinson W., Gardin J., Griffin M.L., Gourevitch M.N., Haller D.L., Hasson A.L., Huang Z., Jacobs P., Kosinski A.S., Lindblad R., McCance-Katz E.F., Provost S.E., Selzer J., Somoza E.C., Sonne S.C., Ling W. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch. Gen. Psychiatry 2011, 68:1238-1246.
64. Woody G.E., Senay E.C., Geller A., Adams E.H., Inciardi J.A., Schnoll S., Munoz A., Cicero T.J. An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride). Drug Alcohol Depend. 2003, 72:163-168.
65. Zacny J.P. Profiling the subjective, psychomotor, and physiological effects of tramadol in recreational drug users. Drug Alcohol Depend. 2005, 80:273-278.
66. Zarghami M., Masoum B., Shiran M.R. Tramadol versus methadone for treatment of opiate withdrawal: a double-blind, randomized, clinical trial. J. Addict. Dis. 2012, 31:112-117.